JP2024517318A5 - - Google Patents
Info
- Publication number
- JP2024517318A5 JP2024517318A5 JP2023569885A JP2023569885A JP2024517318A5 JP 2024517318 A5 JP2024517318 A5 JP 2024517318A5 JP 2023569885 A JP2023569885 A JP 2023569885A JP 2023569885 A JP2023569885 A JP 2023569885A JP 2024517318 A5 JP2024517318 A5 JP 2024517318A5
- Authority
- JP
- Japan
- Prior art keywords
- count
- lowest point
- pharmaceutical composition
- baseline
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163201749P | 2021-05-11 | 2021-05-11 | |
| US63/201,749 | 2021-05-11 | ||
| PCT/US2022/028429 WO2022240786A1 (en) | 2021-05-11 | 2022-05-10 | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517318A JP2024517318A (ja) | 2024-04-19 |
| JP2024517318A5 true JP2024517318A5 (enExample) | 2025-05-16 |
Family
ID=84028499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023569885A Pending JP2024517318A (ja) | 2021-05-11 | 2022-05-10 | アザシチジンと組み合わせて骨髄異形成症候群の処置に使用されるベネトクラクス投与レジメン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220378811A1 (enExample) |
| EP (1) | EP4337183A4 (enExample) |
| JP (1) | JP2024517318A (enExample) |
| KR (1) | KR20240006659A (enExample) |
| CN (1) | CN117642161A (enExample) |
| AU (1) | AU2022273023A1 (enExample) |
| BR (1) | BR112023023677A2 (enExample) |
| CA (1) | CA3219760A1 (enExample) |
| IL (1) | IL308321A (enExample) |
| MX (1) | MX2023013364A (enExample) |
| WO (1) | WO2022240786A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3258941A4 (en) * | 2015-02-17 | 2018-09-26 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
| JP7585231B2 (ja) * | 2019-04-29 | 2024-11-18 | イミュノジェン， インコーポレイテッド | 抗ｃｄ１２３免疫複合体を含む治療的組み合わせ |
| WO2020257671A1 (en) * | 2019-06-20 | 2020-12-24 | Celgene Corporation | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
| WO2021037933A1 (en) * | 2019-08-28 | 2021-03-04 | Astrazeneca Ab | Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer |
| PH12022550835A1 (en) * | 2019-10-18 | 2023-07-03 | Forty Seven Inc | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
-
2022
- 2022-05-10 BR BR112023023677A patent/BR112023023677A2/pt unknown
- 2022-05-10 US US17/741,359 patent/US20220378811A1/en not_active Abandoned
- 2022-05-10 IL IL308321A patent/IL308321A/en unknown
- 2022-05-10 CA CA3219760A patent/CA3219760A1/en active Pending
- 2022-05-10 JP JP2023569885A patent/JP2024517318A/ja active Pending
- 2022-05-10 AU AU2022273023A patent/AU2022273023A1/en not_active Abandoned
- 2022-05-10 WO PCT/US2022/028429 patent/WO2022240786A1/en not_active Ceased
- 2022-05-10 CN CN202280048997.0A patent/CN117642161A/zh not_active Withdrawn
- 2022-05-10 MX MX2023013364A patent/MX2023013364A/es unknown
- 2022-05-10 EP EP22808145.1A patent/EP4337183A4/en not_active Withdrawn
- 2022-05-10 KR KR1020237042682A patent/KR20240006659A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101600438B (zh) | 疼痛疾病治疗剂 | |
| TRABER et al. | Vancomycin ototoxicity in a patient with normal renal function | |
| Leopold et al. | Local and systemic cortisone in ocular disease | |
| JP2022525149A5 (enExample) | ||
| EP0585705A1 (en) | Use of anti-TNF to treat bacterial meningitis | |
| JP2022537551A5 (enExample) | ||
| FI3356386T3 (fi) | Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä | |
| Engqvist et al. | Tranexamic acid in massive haemorrhage from the upper gastrointestinal tract: a double-blind study | |
| JP2005506345A5 (enExample) | ||
| JP2005515214A5 (enExample) | ||
| IL307751B1 (en) | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab | |
| JP2017508737A5 (enExample) | ||
| JP2019507134A5 (enExample) | ||
| EP0630649A1 (en) | Combination of an inhibitor of inducible nitric oxide synthase (iNOS) and an antiinflammatory agent, e.g. a corticosteroid | |
| CA2721728A1 (en) | Treatment of inflammatory bowel disease with 6-mercaptopurine | |
| JPH1017478A (ja) | 潰瘍性大腸炎の予防又は治療剤 | |
| KR20220162821A (ko) | 스테로이드에 대한 내성을 극복하기 위한 글루타르이미드 유도체 | |
| RU2023129202A (ru) | Режимы дозировки венетоклакса для применения в лечении миелодиспластических синдромов в сочетании с азацитидином | |
| Török et al. | Comparative study of a long-acting quinidine preparation and quinidine sulphate in chronic atrial fibrillation | |
| CN116549428B (zh) | 4-羟基异亮氨酸的新用途 | |
| JP4627580B2 (ja) | 肝疾患処置剤 | |
| Assali | Renal effects of hydrochlorothiazide in normal and toxemic pregnancy | |
| JPS61243018A (ja) | 真菌症治療剤 | |
| RU1803119C (ru) | Способ лечени внематочной беременности | |
| IL34670A (en) | Pharmaceutical preparations containing 2-) 2,6-dichlorophenyl-amino (-1,3-diazacicopentane-) 2) and / or its acidic salt salts |